Microbe-based platform aims for sweet spot between biologics and gene therapy A microbe-based therapeutics platform that has been in development for nearly 30 years is gaining traction for the treatment of inflammatory and autoimmune diseases. The company that is developing the platform, Precigen ActoBio, is advancing a lead candidate through clinical trials with the long-term goal of finding a sweet spot between biologics and gene therapies. Discuss
Early trials show potential of Pfizer COVID-19 vaccine Pharmaceutical giant Pfizer is making progress on BNT162b1, a COVID-19 vaccine candidate that is undergoing development and for which the U.S. government has secured access to 300 million doses in 2021. The results of the phase I/II clinical trials were published in Nature on August 12. Discuss
Sharing is caring: Why COVID-19 vaccine manufacturers must collaborate Sharing knowledge between competitors will be key for establishing the manufacturing capacity needed to produce billions of COVID-19 vaccines in coming months. Such collaboration could change the way that innovation and competition are viewed in the biopharmaceutical industry, according to a policy forum published in Science on August 13. Discuss
Thermo Fisher's acquisition of Qiagen falls short Thermo Fisher Scientific has terminated its acquisition of Qiagen after the company was unable to secure the number of shares needed to proceed with the deal. The collapse of the deal kills what would have been one of the largest acquisitions in the scientific and lab instrument space so far this year.
Biosimulation can mitigate risk of COVID-19 drug development Drug development can be an expensive and tedious process. Add in the urgency of the COVID-19 pandemic, and you have a recipe for frustration. Biosimulation -- using computers to simulate drug response in humans -- can help accelerate the process, which Certara hopes to achieve with a newly launched platform targeted at COVID-19 vaccine development. Discuss
New COVID-19 vaccine candidate leverages earlier research Could vaccine platforms developed for previous coronaviruses be converted to address the current COVID-19 pandemic? An August 5 report in Nature described how researchers leveraged previous vaccine research to develop mRNA-1273, a new SARS-CoV-2 vaccine candidate. Discuss
Researchers develop mouse model of COVID-19 infection Researchers have generated a strain of SARS-CoV-2 that can infect mice and used it to produce a new mouse model of infection to help facilitate testing of COVID-19 vaccine candidates and therapies. The research article was published in Science on July 30. Discuss